Naamah Levy Zitomersky, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 6 | 2023 | 2425 | 1.020 |
Why?
|
| Colitis, Ulcerative | 3 | 2023 | 1912 | 0.660 |
Why?
|
| Crohn Disease | 3 | 2023 | 2303 | 0.630 |
Why?
|
| Thromboembolism | 2 | 2014 | 985 | 0.600 |
Why?
|
| Bacteroidetes | 2 | 2014 | 83 | 0.570 |
Why?
|
| Colitis | 2 | 2014 | 1170 | 0.530 |
Why?
|
| Thrombosis | 3 | 2014 | 2968 | 0.500 |
Why?
|
| Antibodies | 2 | 2023 | 2461 | 0.410 |
Why?
|
| Pulmonary Embolism | 2 | 2014 | 2375 | 0.380 |
Why?
|
| Bacteroides | 1 | 2011 | 161 | 0.370 |
Why?
|
| Anticoagulants | 2 | 2014 | 4599 | 0.320 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2011 | 578 | 0.320 |
Why?
|
| Intestines | 2 | 2014 | 1924 | 0.300 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 992 | 0.300 |
Why?
|
| Colon | 2 | 2013 | 1772 | 0.280 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 3036 | 0.180 |
Why?
|
| Gastrointestinal Agents | 1 | 2023 | 494 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 9275 | 0.150 |
Why?
|
| DNA, Bacterial | 2 | 2014 | 1467 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2023 | 956 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2023 | 1582 | 0.120 |
Why?
|
| Hydrolases | 1 | 2015 | 139 | 0.120 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2013 | 62 | 0.120 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2014 | 145 | 0.120 |
Why?
|
| Endotoxemia | 1 | 2015 | 206 | 0.110 |
Why?
|
| Cannabinoids | 1 | 2015 | 166 | 0.110 |
Why?
|
| Bacteroides fragilis | 1 | 2013 | 212 | 0.110 |
Why?
|
| Young Adult | 6 | 2023 | 56436 | 0.100 |
Why?
|
| Vomiting | 1 | 2015 | 635 | 0.100 |
Why?
|
| Factor VIII | 1 | 2013 | 348 | 0.100 |
Why?
|
| Catheters, Indwelling | 1 | 2013 | 425 | 0.100 |
Why?
|
| Marijuana Abuse | 1 | 2015 | 403 | 0.100 |
Why?
|
| Contraceptives, Oral | 1 | 2013 | 563 | 0.100 |
Why?
|
| Adolescent | 7 | 2023 | 85759 | 0.090 |
Why?
|
| Thrombophilia | 1 | 2013 | 305 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2013 | 955 | 0.090 |
Why?
|
| Feces | 2 | 2014 | 1402 | 0.080 |
Why?
|
| Thalidomide | 1 | 2013 | 890 | 0.080 |
Why?
|
| Catheterization | 1 | 2013 | 1469 | 0.080 |
Why?
|
| Immunity, Mucosal | 1 | 2011 | 490 | 0.080 |
Why?
|
| Awareness | 1 | 2011 | 640 | 0.070 |
Why?
|
| Child | 4 | 2023 | 77679 | 0.070 |
Why?
|
| Female | 10 | 2023 | 380197 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 53280 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2013 | 3461 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 6172 | 0.050 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2001 | 118 | 0.050 |
Why?
|
| Hepatoblastoma | 1 | 2001 | 87 | 0.050 |
Why?
|
| Biopsy | 1 | 2013 | 6757 | 0.050 |
Why?
|
| Sepsis | 1 | 2015 | 2593 | 0.050 |
Why?
|
| Male | 8 | 2018 | 350027 | 0.050 |
Why?
|
| Humans | 11 | 2023 | 744220 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 5867 | 0.040 |
Why?
|
| Wilms Tumor | 1 | 2001 | 373 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2018 | 379 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 25043 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2015 | 21752 | 0.040 |
Why?
|
| Smoking | 1 | 2013 | 8986 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 1999 | 634 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 6485 | 0.030 |
Why?
|
| Adult | 4 | 2015 | 214035 | 0.030 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2015 | 35 | 0.030 |
Why?
|
| Incidence | 1 | 2013 | 20945 | 0.030 |
Why?
|
| Amitriptyline | 1 | 2015 | 110 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 25618 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1999 | 952 | 0.030 |
Why?
|
| Infant | 2 | 2015 | 35129 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 29050 | 0.030 |
Why?
|
| Conjugation, Genetic | 1 | 2014 | 126 | 0.030 |
Why?
|
| Neutrophil Activation | 1 | 2015 | 186 | 0.030 |
Why?
|
| Prevalence | 1 | 2011 | 15226 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2015 | 791 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2015 | 40992 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39045 | 0.030 |
Why?
|
| Peritonitis | 1 | 2015 | 365 | 0.030 |
Why?
|
| AIDS Vaccines | 1 | 1999 | 938 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2015 | 981 | 0.030 |
Why?
|
| Disabled Children | 1 | 2015 | 247 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 1999 | 1322 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 17449 | 0.030 |
Why?
|
| Methotrexate | 1 | 2018 | 1720 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2015 | 1458 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 2272 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 526 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 23337 | 0.020 |
Why?
|
| Bacteremia | 1 | 2015 | 962 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 1255 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 2216 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 72280 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 4252 | 0.020 |
Why?
|
| Boston | 1 | 2018 | 9311 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4245 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2013 | 77426 | 0.020 |
Why?
|
| Histones | 1 | 2015 | 2600 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12244 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 5974 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13409 | 0.010 |
Why?
|
| Neutrophils | 1 | 2015 | 3717 | 0.010 |
Why?
|
| Glypicans | 1 | 2001 | 34 | 0.010 |
Why?
|
| HIV-1 | 1 | 1999 | 6938 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 18116 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 3849 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2015 | 14556 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 769 | 0.010 |
Why?
|
| Aged | 1 | 2011 | 163253 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1999 | 311 | 0.010 |
Why?
|
| Papio | 1 | 1999 | 656 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2892 | 0.010 |
Why?
|
| Middle Aged | 1 | 2011 | 213367 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 21824 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 7179 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 7659 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10634 | 0.010 |
Why?
|
| Immunization | 1 | 1999 | 1256 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4752 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 5180 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 6612 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3703 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 81178 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 11007 | 0.000 |
Why?
|
| Animals | 2 | 2015 | 168788 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 2001 | 13036 | 0.000 |
Why?
|